The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio’s PRV; RMAT Designation For PolarityTE’s Product
Here's a roundup of top developments in the biotech space over the last 24 hours:
Cowen & Co. Initiates Coverage On EQRx with Outperform Rating
Cowen & Co. analyst Steve Scala initiates coverage on EQRx (NASDAQ:EQRX) with a Outperform rating.
Earnings Scheduled For March 23, 2022
Companies Reporting Before The Bell
• AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter.
75 Biggest Movers From Yesterday
Gainers
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 95 companies set new 52-week lows.
78 Biggest Movers From Friday
Gainers
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab.
Cramer Gives His Opinion On ADT, Occidental Petroleum And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said EQRx, Inc. (NASDAQ: EQRX) needs to be bought. "It shouldn't be independent," he added.